Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 16/20 | 1.00 |
| ▸ | UCHL1 | P09936 | 14/20 | 1.00 |
| ▸ | CTSB | P07858 | 5/20 | 1.00 |
| ▸ | CTSK | P43235 | 5/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 1.00 |
| ▸ | CTSC | P53634 | 3/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644758 | 1.00 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL20576333 | 1.00 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL21989967 | 0.92 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL21989969 | 0.92 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL21989980 | 0.92 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL6859742 | 0.86 | UCHL1 (0.93) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL6859911 | 0.86 | USP30 (0.76) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3818016 | 0.84 | CTSB (0.74) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3815699 | 0.84 | CTSB (0.74) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3810898 | 0.84 | CTSK (1.00) | USP30UCHL1CTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | claimed |
| EP-3630096-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | Mission Therapeutics Limited (GB) | 2020-04-08 | — | — | EP | claimed |
| CN-110678176-A | Sulfonamide substituted cyanopyrrolidines with DUB inhibitor activity | 特殊治疗有限公司 | 2020-01-10 | — | — | CN | claimed |
| WO-2018220355-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-06 | — | — | WO | claimed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | claimed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | claimed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | claimed |
| CN-110678176-B | Sulfonamide substituted cyanopyrrolidines with DUB inhibitor activity | 特殊治疗有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11414402-B2 | Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-08-16 | — | — | US | disclosed |
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3630096-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | Mission Therapeutics Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| CN-110678176-A | Sulfonamide substituted cyanopyrrolidines with DUB inhibitor activity | 特殊治疗有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | disclosed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | disclosed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | USP30, USP1, USP39 | USP30 1/4885UCHL1 5/4885CTSB 1107/4885 |
| US-20090264499-A1 | Cathepsin C Inhibitors | CTSB, CTSF, CTSG | USP30 1138/4885UCHL1 159/4885CTSB 1/4885 |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | CTSK, CTSZ, CTSE | USP30 374/4885UCHL1 110/4885CTSB 5/4885 |
| US-11414402-B2 | Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors | USP30, USP1, USP39 | USP30 1/4885UCHL1 5/4885CTSB 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.